title: Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies.
abstract: The blockade of immune regulatory checkpoints is emerging as a powerful anticancer strategy. We recently reported long-term results from the first-in-human clinical trial of anti-PD1 antibody-based immunotherapy, demonstrating durable tumor control off-therapy in subjects affected by colorectal and kidney cancer, as well as successful re-induction therapy in a melanoma patient.
authors.affiliation: Department of Oncology; Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center; Baltimore, MD USA.
authors.forename: Evan J
authors.initials: EJ
authors.lastname: Lipson
keywords: anti-PD1; cancer immunotherapy; immune checkpoint blockade; nivolumab; re-induction